KALA - Kala Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.08
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.08
Open6.09
Bid0.00 x 800
Ask0.00 x 1400
Day's Range5.95 - 6.22
52 Week Range4.03 - 14.45
Volume157,966
Avg. Volume184,143
Market Cap206.008M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Is Expected To Breakeven
    Simply Wall St.last month

    Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Is Expected To Breakeven

    Kala Pharmaceuticals, Inc.'s (NASDAQ:KALA): Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the...

  • Kala Pharmaceuticals, Inc. (KALA) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Kala Pharmaceuticals, Inc. (KALA) Q1 2019 Earnings Call Transcript

    KALA earnings call for the period ending March 31, 2019.

  • Kala Pharmaceuticals (KALA) Reports Q1 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Kala Pharmaceuticals (KALA) Reports Q1 Loss, Tops Revenue Estimates

    Kala Pharma (KALA) delivered earnings and revenue surprises of 17.28% and 43.78%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Kala Pharma: 1Q Earnings Snapshot

    The Watertown, Massachusetts-based company said it had a loss of 75 cents per share. Losses, adjusted for stock option expense and non-recurring costs, came to 67 cents per share. The results topped Wall ...

  • Is the Options Market Predicting a Spike in Kala Pharmaceuticals (KALA) Stock?
    Zacks3 months ago

    Is the Options Market Predicting a Spike in Kala Pharmaceuticals (KALA) Stock?

    Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.

  • Investors Who Bought Kala Pharmaceuticals (NASDAQ:KALA) Shares A Year Ago Are Now Down 52%
    Simply Wall St.3 months ago

    Investors Who Bought Kala Pharmaceuticals (NASDAQ:KALA) Shares A Year Ago Are Now Down 52%

    It is doubtless a positive to see that the Kala Pharmaceuticals, Inc. (NASDAQ:KALA) share price has gained some 42% in the last three months. But that's not enough to compensate for the decline over the last twelve months...

  • Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options
    Zacks4 months ago

    Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options

    Kala Pharmaceuticals (KALA) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Associated Press4 months ago

    Kala Pharma: 4Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 76 cents. Losses, adjusted to extinguish debt, were 75 cents per share. The results did not meet Wall Street expectations. ...

  • Kala Pharmaceuticals, Inc.’s (NASDAQ:KALA) Path To Profitability
    Simply Wall St.6 months ago

    Kala Pharmaceuticals, Inc.’s (NASDAQ:KALA) Path To Profitability

    Kala Pharmaceuticals, Inc.'s (NASDAQ:KALA): Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment Read More...

  • Associated Press8 months ago

    Kala Pharma: 3Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 63 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Kala Pharmaceuticals (KALA) Catches Eye: Stock Jumps 7.4%
    Zacks9 months ago

    Kala Pharmaceuticals (KALA) Catches Eye: Stock Jumps 7.4%

    Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • Here's Why Kala Pharmaceuticals Fell as Much as 17.7% Today
    Motley Fool9 months ago

    Here's Why Kala Pharmaceuticals Fell as Much as 17.7% Today

    The pharma company announced the pricing of a share offering.

  • Is Kala Pharmaceuticals Inc’s (NASDAQ:KALA) Balance Sheet A Threat To Its Future?
    Simply Wall St.10 months ago

    Is Kala Pharmaceuticals Inc’s (NASDAQ:KALA) Balance Sheet A Threat To Its Future?

    Kala Pharmaceuticals Inc (NASDAQ:KALA) is a small-cap stock with a market capitalization of US$266.8m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they Read More...

  • TheStreet.com10 months ago

    Six Biotechnology Names on My Watch List

    The indices have been slowly drifting lower after a gap up open. Early breadth was around 3 to 1 positive but its now down to around 4-3 positive. The bulls are not producing much positive momentum but the bears are doing an even worse job of producing negative momentum.

  • Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA
    Zacks11 months ago

    Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA

    Regulatory and pipeline updates comprise some of the key developments in the biotech sector this week. These include Gilead's Yescarta approval in Europe.

  • Reuters11 months ago

    U.S. FDA approves Kala Pharma's eye pain drug

    The U.S. Food and Drug Administration on Thursday approved Kala Pharmaceuticals Inc's treatment for reducing inflammation and pain following an eye surgery. The company said it expects to launch the drug, Inveltys, in the beginning of 2019, with Wedbush Securities estimating peak sales of about $271 million in 2027. The drug was found to have no serious side effects during clinical trials, Kala said.

  • H.C. Wainwright Maintains Buy on Kala Pharmaceuticals (KALA) Ahead of Upcoming PDUFA Date
    SmarterAnalyst11 months ago

    H.C. Wainwright Maintains Buy on Kala Pharmaceuticals (KALA) Ahead of Upcoming PDUFA Date

    H.C. Wainwright analyst Ram Selvaraju is out this morning with another bullish note on shares of Kala Pharmaceuticals (NASDAQ:KALA), reiterating a Buy rating and price target of $35, which represents a potential upside of 197% from where the stock is currently trading.Selvaraju continues to see a favorable risk/reward profile on Kala heading into the August 24 PDUFA date for lead candidate, INVELTYS. If approved, INVELTYS would be the first FDA-approved corticosteroid eye drop with a twice daily dosing regimen for the treatment of post-operative ocular inflammation and pain.Selvaraju wrote, "We project INVELTYS to be launched in 1H19 and generate $36M in revenue during 2019. In our view, the combination of LE’s safety profile and dosing convenience should allow INVELTYS to seize market share from branded eye drops such as Lotemax and Durezol, as well as generic prednisolone. INVELTYS would also hold a competitive advantage vs. Dextenza (PDUFA date December 28, 2018) and DEXYCU (FDA-approved), if the latter two were also to enter the market in 2019. We note that, at commercial launch, Dextenza would only be indicated for ocular pain, and DEXYCU would only be indicated for ocular inflammation. In addition, dexamethasone (the API in both Dextenza and DEXYCU) is known to induce increased intraocular pressure (IOP) more often than LE.""Our 12-month price target is derived from a market value of the firm at $1.0B, which includes a discounted cash flow-based asset value of $1.1B for INVELTYS (85% probability of success) and KPI-121 0.25% (65% probability of success), with a 15% discount rate and 0.5% terminal growth rate," the analyst added.When it comes to Wall Street’s bet, the odds are on this biotech player, with TipRanks analytics showcasing KALA as a Strong Buy. Out of 4 analysts polled in the last 12 months, all 4 are bullish on Kala stock. With a return potential of nearly 188%, the stock’s consensus target price stands at $34. More recent articles from Smarter Analyst: * Cantor Fitzgerald Thinks Aldeyra Therapeutics' Stock is Going to Recover * Roth Capital Keeps Their Buy Rating on Digital Turbine Inc (APPS) * McCormick & Company (MKC) Receives a Buy from Jefferies * Autodesk (ADSK) Received its Third Buy in a Row

  • Associated Press11 months ago

    Kala Pharma: 2Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 60 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • Kala Pharmaceuticals (KALA), Durect (DRRX), and Amarin (AMRN) Reiterated with a Buy at H.C. Wainwright
    SmarterAnalyst11 months ago

    Kala Pharmaceuticals (KALA), Durect (DRRX), and Amarin (AMRN) Reiterated with a Buy at H.C. Wainwright

    In a research note issued Wednesday, H.C. Wainwright analyst Ram Selvaraju reiterated coverage on shares of Kala Pharmaceuticals (NASDAQ:KALA), with a Buy rating and price target of $35, which represents a potential upside of 173% from where the stock is currently trading. The reiteration follows the news that the company's third phase 3 trial (STRIDE 3) of KPI-121 0.25% for the treatment of dry eye disease (DED), had dosed its first patient.Selvaraju wrote, "The STRIDE 3 trial design has specific modifications to the inclusion/exclusion criteria to address key factors that could improve the probability of success, according to management. Investors may recall that KPI-121 0.25% did not meet the primary symptom endpoint in one of the two previously-completed Phase 3 trials. In our view, STRIDE 3 would need to meet the symptom endpoint, but not necessarily the sign endpoint, to be considered sufficient to complete the New Drug Application (NDA) package. Thus, the STRIDE 3 trial design could have been optimized to increase the probability of meeting the primary symptom endpoint. We continue to believe that KPI-121 0.25% could obtain regulatory approval in 2020 and become the first FDA-approved product for short-term treatment of DED."In addition, Kala has a key catalyst on its hands this summer when it comes to lead asset INVELTYS (KPI-121 1%), designed to treat patients with post-surgical ocular inflammation and pain. KALA's INVELTYS has a PDUFA date set for August 24 and the analyst expects 85% odds that the treatment gets a green light. If approved, INVELTYS would be the first FDA-approved corticosteroid eye drop with a twice-daily dosing regimen.The analyst also maintained coverage on Durect (NASDAQ:DRRX) with a Buy rating and a $3.00 price target, following the news that Durect partner Indivior received FDA approval for PERSERIS, the first once monthly subcutaneous risperidone-containing, long-acting injectable for the treatment of schizophrenia in adults.Finally, H.C. Wainwright's Andrew Fein affirmed a Buy rating on shares of Amarin (NASDAQ:AMRN), with a $10 price target, as he sees attractive risk/return profile ahead of REDUCE-IT topline data, which is about to be released this September. More recent articles from Smarter Analyst: * Stifel on Amarin (AMRN): Nothing Fishy About This Stock -- It's a Buy! * Amarin (AMRN): New Survey Offers Insight Into Vascepa Market Opportunity * Should You Buy Amarin (AMRN) Stock? 4 Pros, 4 Cons * Amarin (AMRN): Management Is Flying in the Dark

  • According to H.C. Wainwright, This Biotech Stock Can Jump to $35
    SmarterAnalystlast year

    According to H.C. Wainwright, This Biotech Stock Can Jump to $35

    It's been tough sledding for Kala Pharmaceuticals (NASDAQ:KALA) shareholders. The company's share price has lost approximately 46% year-to-date due to the fact that its second Phase 3 trial in dry eye disease (DED) did not meet the symptom endpoint.However, H.C. Wainwright analyst Ram Selvaraju believes that Kala's current valuation provides an intriguing entry point for investors ahead of what the analyst considers to be a risk-mitigated catalyst—the potential approval of INVELTYS for post-surgical ocular inflammation and pain. Since this candidate is based on a well-known, validated corticosteroid that has been used for many years in ocular applications, and given the fact that the NDA was filed via the 505(b)(2) regulatory pathway, Selvaraju has high confidence that INVELTYS should be approved by August 24 (the PDUFA date).As such, Selvaraju launches coverage on KALA, awarding it a Buy rating with a $35 price target, which represents a 177% upside from current levels.Selvaraju wrote, "The potential approval of INVELTYS in August would be a major milestone for Kala, as it would turn the company into a commercial-stage organization. Kala plans to launch INVELTYS in the U.S. in 2019 with its own sales and marketing team, which could initially consist of 75 individuals. The company would also partner with potential distributors in other global markets. We estimate that peak sales of INVELTYS post-cataract surgery procedures in the U.S. alone could approach $280 million in 2029.""In our view, Kala constitutes an attractive opportunity in the ophthalmology space because of the late-stage status of INVELTYS and the potential for the company to build on the possible nearterm approval of this product by advancing its pipeline. We note that the DED and retinal disease arenas appear to be sparsely-populated and relatively inefficiently addressed with current therapy. Success on multiple fronts could make Kala attractive to more established companies in the ophthalmology domain, in our view," the analyst concluded.Overall, Wall Street’s confidence backing this biotech player is strong, with TipRanks analytics showcasing KALA as a Strong Buy. Based on 5 analysts polled in the last 12 months, all 5 rate a Buy on the stock. The 12-month average price target stands at $33.80, marking a nearly 168% upside from where the stock is currently trading.

  • Kala Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
    Zackslast year

    Kala Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

    Kala Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?